Optimal dose for topical use of tranexamic acid after cardiovascular surgery

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0004211

Enrollment

123

Registered

2019-08-19

Start date

2023-01-20

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : If a cardiac and cardiovascular surgery is carried out in the same way as a conventional surgery and it is determined that there are no more bleeding areas, the assigned test drug is applied ar

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -An adult who has been operated on for heart and aortic disease -Men and women aged 19 and over -Those who voluntarily agree to this study

Exclusion criteria

Exclusion criteria: -In case of preoperative antifibrinolytics used -In case who was diagnosed with preoperative blood clot disease -In case of liver cirrhosis -Patients with thrombotic thrombosis and such a history -Patients who overreact to this drug and its constituent parts

Design outcomes

Primary

Measure	Time frame
Bleeding flow (verified by blood test)	—

Secondary

Measure	Time frame
Blood transfusion flow;arterial blood gas analysis;Chest tube drainage;Cardiac ultrasonography;surgical complication;Survival status	—

Countries

Korea, Republic of

Contacts

Public ContactHoSung Son

Korea University Anam Hospital

hssonmd@gmail.com+82-2-920-6453

Outcome results